Intellectual PropertyAPIM Therapeutics holds an IP portfolio broadly covering its therapeutic focus areas, new therapeutics and treatment methods in relation hereto. This includes a patent application featuring the use of APIM-motif comprising peptide compounds as novel therapeutic agents for the treatment of cancer and other hyper-proliferative disorders (granted in the US, Japan, Australia, Korea, Russia and other countries). Furthermore, the Company has certain rights to new developments, improvements and new inventions in the field based on the ongoing research at NTNU.



APIM Therapeutics is committed to developing a broad international patent portfolio that ensures maximum protection of its products for the benefit of its shareholders.